RPS6KA1 (Ab-352) Antibody

What is RPS6KA1 and why is it important in cellular signaling?

RPS6KA1 (also known as p90RSK1, RSK1, or MAPKAP kinase 1a) is a 90 kDa ribosomal protein S6 kinase that functions as a downstream effector in the MAPK/ERK signaling pathway. It plays crucial roles in regulating cell growth, proliferation, differentiation, survival, and motility through phosphorylation of various substrates . As a key mediator in cellular signaling, RPS6KA1 is activated through sequential phosphorylation by ERK1/2, PDK1, and autophosphorylation within its functional domains . The importance of RPS6KA1 lies in its regulation of diverse cellular processes and its emerging role in disease mechanisms, particularly in cancer therapy resistance .

What are the recommended applications for RPS6KA1 (Ab-352) antibody?

The RPS6KA1 (Ab-352) antibody has been validated for several experimental applications with specific recommended dilutions:

This polyclonal antibody recognizes the peptide sequence around amino acids 350-354 (R-D-S-P-G) derived from p90RSK, making it suitable for detecting both total and potentially some phosphorylated forms of RPS6KA1 .

How should researchers prepare samples for optimal RPS6KA1 (Ab-352) antibody detection?

For optimal detection using the RPS6KA1 (Ab-352) antibody, researchers should consider:

• Cell/tissue lysis: Use a buffer containing phosphatase inhibitors (especially for studying phosphorylated forms) and protease inhibitors to prevent protein degradation.

• Protein quantification: Ensure equal loading of samples using Bradford or BCA assays.

• For Western blotting:

  • Suggested protein amount: 20-40 μg per lane

  • Recommended blocking solution: 5% non-fat milk or BSA in TBST

  • Incubation conditions: Primary antibody at 4°C overnight at recommended dilution

For immunohistochemistry, antigen retrieval methods should be optimized, typically using citrate buffer (pH 6.0) or EDTA buffer (pH 8.0) for formalin-fixed paraffin-embedded tissues to expose the epitope.

What controls should be included when using RPS6KA1 (Ab-352) antibody?

When using RPS6KA1 (Ab-352) antibody, the following controls should be included to ensure valid results:

• Positive control: Tissues or cell lines known to express RPS6KA1 (human cancer cell lines like OCI-AML2 have been documented)

• Negative control: Omission of primary antibody or use of isotype control (rabbit IgG)

• Validation control: RPS6KA1 knockdown/knockout samples where available (using siRNA or CRISPR-Cas9)

• Loading control: For Western blotting, include detection of housekeeping proteins (β-actin, GAPDH)

These controls help validate antibody specificity and ensure that observed signals are truly representative of RPS6KA1 expression or modifications.

How can RPS6KA1 (Ab-352) antibody be used to study phosphorylation states?

Understanding the phosphorylation state of RPS6KA1 is critical since its activity is regulated through multiple phosphorylation events. The Ab-352 antibody recognizes a region that includes significant phosphorylation sites:

• While the Ab-352 antibody is not phospho-specific, researchers can use it in conjunction with phospho-specific antibodies in parallel experiments to determine total vs. phosphorylated RPS6KA1 ratios.

• For studying specific phosphorylation events, researchers should design experiments using:

  • Phosphatase treatment: Compare antibody recognition before and after phosphatase treatment

  • Phosphomimetic mutants: Generate S352D/E mutants to mimic phosphorylation

  • Mass spectrometry validation: Use phosphopeptide enrichment followed by MS analysis to validate phosphorylation status

The Ser352 phosphorylation (Ser363 in human RSK1) is particularly significant as it represents an ERK target site critical for RSK activity . When studying this phosphorylation, researchers should employ both the Ab-352 antibody and phospho-specific antibodies to correlate total protein levels with activation status.

What is the significance of RPS6KA1 in cancer therapy resistance and how can the antibody aid this research?

Recent research has identified RPS6KA1 as a mediator of resistance to venetoclax/azacitidine treatment in acute myeloid leukemia (AML) . The RPS6KA1 (Ab-352) antibody can be instrumental in investigating this phenomenon through:

• Expression analysis: Quantifying RPS6KA1 levels in resistant vs. sensitive tumor samples

• Pharmacological studies: Monitoring RPS6KA1 expression/activity changes following treatment with inhibitors like BI-D1870

• Mechanistic investigations: Identifying downstream targets affected by RPS6KA1 inhibition

Studies have shown that pharmacological inhibition of RPS6KA1 increases sensitivity to venetoclax/azacitidine in parental AML cells and can restore sensitivity in resistant AML cells . Using the RPS6KA1 (Ab-352) antibody in combination with cell viability assays, researchers can correlate RPS6KA1 expression levels with treatment response to develop more effective therapeutic strategies.

How does RPS6KA1 modulate ERK signaling and what experimental approaches can detect this interaction?

RPS6KA1 functions within a negative feedback loop that modulates ERK signaling. Research has shown that RSK-depleted ES cells exhibit elevated ERK phosphorylation, suggesting that RSK1 normally suppresses ERK activity . To study this relationship:

• Co-immunoprecipitation (Co-IP): Use RPS6KA1 (Ab-352) antibody to pull down protein complexes and probe for ERK interaction

• Proximity ligation assay (PLA): Visualize RPS6KA1-ERK interactions in situ

• Genetic approaches: Analyze changes in ERK phosphorylation in RPS6KA1 knockout models

A recommended experimental workflow includes:

• Genetic knockout or knockdown of RPS6KA1 using CRISPR/Cas9 or siRNA

• Western blot analysis of pERK levels in wild-type versus knockout cells

• Rescue experiments by reintroducing RPS6KA1 to confirm specificity of effect

Studies using CRISPR/Cas9-mediated knockout of Rps6ka1 demonstrated significantly elevated pERK levels, which could be restored to normal by reintroducing the RPS6KA1 gene . This experimental approach provides strong evidence for RPS6KA1's role in ERK signaling regulation.

What are common issues when using RPS6KA1 (Ab-352) antibody and how can they be resolved?

Researchers may encounter several challenges when working with RPS6KA1 (Ab-352) antibody:

For cross-reactivity concerns, note that the RPS6KA1 (Ab-352) antibody may detect other RSK family members due to sequence homology. When absolute specificity is required, validate results using genetic approaches (knockout/knockdown) or alternative antibodies targeting different epitopes.

How can researchers distinguish between different RSK isoforms?

The RSK family consists of four members (RSK1-4) with high sequence homology. To distinguish RPS6KA1 (RSK1) from other isoforms:

• Isoform-specific knockdown: Use siRNA targeting unique regions of each RSK isoform

• Western blotting comparison: Run recombinant RSK1-4 proteins alongside samples

• Mass spectrometry analysis: Identify isoform-specific peptides following immunoprecipitation

When studying RSK1 phosphorylation, consider that phosphorylation patterns may differ between isoforms. For example, while Ser352 phosphorylation was significantly affected by MEK inhibitor withdrawal in RSK1, a similar site (Ser352) in RSK2 (Rps6ka3) was not significantly affected, indicating differential regulation .

What methodological approaches can optimize RPS6KA1 (Ab-352) antibody for multiplex immunofluorescence studies?

For multiplex detection involving RPS6KA1 (Ab-352) antibody:

• Antibody labeling: Consider direct labeling with fluorophores to avoid species cross-reactivity

• Sequential staining: When using multiple rabbit antibodies, employ tyramide signal amplification with intervening microwave treatment

• Spectral unmixing: Use confocal microscopy with appropriate filter sets to distinguish overlapping signals

Optimization steps include:

• Titration of antibody concentration specifically for immunofluorescence

• Testing multiple antigen retrieval methods

• Validation with appropriate controls (including single-stained samples for spectral unmixing)

What is the optimal experimental design for studying RPS6KA1 inhibition in cancer models?

When investigating RPS6KA1 inhibition in cancer models, consider this comprehensive experimental framework:

• Expression analysis:

  • Quantify RPS6KA1 expression levels across cancer cell lines using the Ab-352 antibody

  • Compare with patient-derived samples to establish clinical relevance

• Functional studies:

  • Genetic approaches: CRISPR/Cas9 knockout or siRNA knockdown of RPS6KA1

  • Pharmacological inhibition: Treatment with RSK inhibitors (e.g., BI-D1870)

  • Rescue experiments with wild-type or mutant RPS6KA1 to confirm specificity

• Therapeutic relevance assessment:

  • Combination studies with standard-of-care treatments (e.g., venetoclax/azacitidine for AML)

  • Analysis of cell surface markers to identify responsive subpopulations

  • In vivo validation using xenograft models

Research has demonstrated that RPS6KA1 inhibition with BI-D1870 completely restored sensitivity of OCI-AML2 cells with acquired resistance to venetoclax/azacitidine, particularly targeting monocytic blast subclones that could be sources of relapse .

How can phosphoproteomics approaches complement RPS6KA1 (Ab-352) antibody studies?

Integrating phosphoproteomics with RPS6KA1 antibody studies provides a comprehensive view of signaling networks:

• Sample preparation workflow:

  • Cell fractionation to increase phosphopeptide coverage (cytoplasmic S1 and nuclear N1 fractions)

  • Protein extraction and trypsin digestion

  • Phosphopeptide enrichment using strong cation exchange chromatography followed by TiO₂ affinity purification

• Mass spectrometry analysis:

  • Use high-resolution instruments (e.g., Orbitrap) for precise identification

  • Implement MaxQuant software for quantitation of phosphorylated proteins

  • Apply statistical analysis to identify significantly regulated phosphosites

• Data integration:

  • Compare antibody-based detection with MS-identified phosphopeptides

  • Map RPS6KA1 phosphorylation to downstream substrate regulation

  • Construct signaling pathway models based on integrated data

This approach has successfully identified RPS6KA1 Ser352 phosphorylation as significantly regulated (adj P-value = 0.019) in response to MEK inhibitor withdrawal, with approximately fivefold increase in phosphorylation at this critical ERK target site .

What are the recommended approaches for validating RPS6KA1 (Ab-352) antibody specificity?

To ensure experimental validity, thoroughly validate the specificity of RPS6KA1 (Ab-352) antibody using these approaches:

• Genetic validation:

  • Compare detection in wild-type versus RPS6KA1 knockout/knockdown models

  • Perform rescue experiments by reintroducing wild-type or mutant RPS6KA1

• Peptide competition:

  • Pre-incubate antibody with the immunizing peptide (aa.350-354, R-D-S-P-G) before application

  • Compare signal with and without peptide competition

• Multiple antibody validation:

  • Compare results using antibodies targeting different RPS6KA1 epitopes

  • Correlate total protein detection with phospho-specific antibody results

• Orthogonal methods:

  • Validate protein expression using mass spectrometry

  • Confirm functional effects through activity assays

When conducting validation studies, remember that the specificity of polyclonal antibodies may vary between lots, necessitating validation for each new lot received.

How should researchers interpret contradictory results between RPS6KA1 antibody detection and functional assays?

When faced with discrepancies between antibody detection and functional outcomes:

• Consider post-translational modifications:

  • The Ab-352 antibody detects total protein regardless of activation state

  • Functional outcomes may depend on specific phosphorylation patterns not reflected in total protein levels

• Evaluate compensatory mechanisms:

  • Other RSK family members may compensate for RPS6KA1 in knockout/knockdown models

  • Cross-talk with parallel signaling pathways may mask expected phenotypes

• Investigate technical limitations:

  • Antibody may recognize degradation products or specific conformations

  • Cell fractionation quality may affect detection of nuclear versus cytoplasmic pools

• Resolution strategies:

  • Employ multiple complementary techniques (WB, IP-MS, activity assays)

  • Compare acute (inhibitor) versus chronic (genetic) loss of function

  • Analyze temporal dynamics of signaling responses

Studies have shown that different mutant combinations of RSK family members have varying effects on pERK levels, highlighting the complexity of these signaling networks and the need for comprehensive analysis .